

Quality choice with reputation effects: Evidence from hospices in California

Rubaiyat Alam*

[\(Link to latest version\)](#)

October 20, 2022

Abstract

Hospices - firms which give palliative care to dying patients - are a large and growing industry in US, with significant implications for patient welfare and cost savings. Hospices are reimbursed at a fixed price per patient by Medicare, with expenses totaling over \$21 billion in 2019. I use annual firm-level data from California to study quality choice by hospices under reputation effects and explore counterfactual policies to improve hospice quality. Hospice quality is measured by the average visits-per-patient in a year. I define reputation of a hospice to be a nonlinear function of its past quality choices, meaning that a hospice can accumulate reputation over time by consistently choosing high quality. To see if reputation matters to consumers, I first estimate a structural model of hospice choice by consumers. Reputation has a strong influence on consumer demand but decays at an annual rate of 53%. I incorporate this into a dynamic oligopoly model of hospices choosing quality to compete on reputation against rivals, and estimate it to recover hospices' cost functions. An additional visit costs a hospice around \$200, for-profits enjoy an efficiency advantage over non-profits, and hospices in rural counties suffer a cost disadvantage compared to those in urban counties. I solve the model to find hospice quality choices under alternative policy environments. As reputation becomes more persistent, hospices choose higher quality. Hospices also choose higher quality as Medicare prices increase, but the response depends on how differentiated it is in terms of characteristics from its rivals. A hybrid per-day per-visit hospice reimbursement scheme can achieve the same quality at a lower cost than the current per-day scheme.

*Email: ralam@bu.edu. I am grateful to Marc Rysman for his time and invaluable guidance, without which this project would not have been possible. Thanks to Jihye Jeon, Randy Ellis, Albert Ma, Eric Hardy, Chuqing Jin, Tim Lee, Kevin Lang, Ginger Jin, Peter Deffebach, Michael Manove, and participants at seminars in Boston University.

1 Introduction

Hospices give palliative care to dying patients by visiting them and helping with pain control and living arrangements. This is a useful industry to study for the following reasons. First, it is a large and growing industry - over 1.6 million Medicare patients used hospices in 2022, Medicare spent around \$21 billion on hospice services in 2019, and the Affordable Care Act has sought to increase hospice usage. However, concerns have been raised about hospice quality across US.¹ Improving hospice quality will result in improvement of hospice patient welfare, as well as cause many patients to switch away from ineffective and painful curative treatments. Second, the hospice industry is a regulated-price setting since Medicare reimburses hospices a fixed rate for every patient. Such regulated price settings are common in US (like Medicare’s DRG scheme) and across the world (such as in UK, Germany and France), and so the hospice industry can give insights on firm behavior and especially policy design for regulated-price healthcare markets. Third, it is a great setting for studying how reputation affects consumer and firm choices. In this context, the reputation of a hospice can be thought of as reflecting its past quality choices. A hospice can therefore choose to provide high quality of service to build up its reputation over time and attract consumers. Such reputation effects are expected to be prevalent in other healthcare markets as well, and by studying hospices we can shed light on quality choice under reputation effects.

Using firm-level data from California, I study quality choice by hospices, uncover the importance of hospice reputation for consumers, and explore counterfactual policies that can incentivize higher hospice quality. I build and estimate a structural model of consumer demand and hospice quality choice to do so. My measure of hospice quality is the average number of visits made by a hospice to its patients in a year, and I define reputation of a hospice to be a function of its current and past quality choices. I use my structural model to quantify the importance of reputation for consumers choosing hospices and calculate hospices’ cost functions. Reputation plays an important role in consumer demand for hospices, and past reputation decays at an annual rate of 53%. The cost of an additional visit by a hospice to a patient is roughly \$200, for-profits enjoy an efficiency advantage over non-profits, and rural hospices suffer from a cost disadvantage compared to urban hospices. Counterfactuals show that hospice quality increases with higher Medicare prices and greater persistence of reputation through review sites. I compare the current per-day Medicare reimbursement scheme with a hybrid per-day per-visit scheme, and find that the latter can incentivize the same level of hospice quality at lower cost.

¹The Department of Health and Human services has released a report citing numerous deficiencies in hospice quality: <https://oig.hhs.gov/newsroom/media-materials/media-materials-2019-hospice/>.

Hospices give care to dying patients by visiting them at their residences, where they administer pain medication and help with living arrangements. More visits by the hospice staff can be thought of as implying higher quality - it means the hospice is checking up on patients more and adjusting for day-to-day difficulties. Hospice care is a great setting for studying reputation because 1) visits vary a lot across hospices, 2) price is set by Medicare which simplifies the analysis, and 3) reputation is expected to be important in medical settings. Hospices which have given higher quality care in the past are more likely to be known and referred within the community. This suggests that a hospice can build up its reputation by persistently choosing high quality over time, and use this higher reputation to attract more patients.

I build a structural model of hospice demand by consumers and quality choice by hospices. Reputation of a hospice is defined to be a nonlinear function of its current and past quality choices. Each consumer makes a discrete choice from a set of hospices in their market. Their choice is influenced by hospices' reputations and characteristics. In response, hospices choose quality every period, taking into account that a higher quality will lead to higher reputation and sales but also higher cost per consumer.

I estimate this model using yearly hospice-level data from California for 2002-2018. The nested-logit discrete choice demand model is estimated following the inversion of [Berry \(1994\)](#) and allowing for persistent unobserved demand shocks. This lets me pin down the magnitude and persistence of reputation in hospice choice. The estimated demand model shows that reputation plays a significant role in consumer choice and decays at an annual rate of 53%. I then estimate a dynamic oligopoly model of quality choice which incorporates the estimated reputation effects. The estimation method follows [Bajari et al. \(2007\)](#). This clarifies how forward-looking hospices choose quality over time in a strategic setting, and gives me point estimates of cost parameters. I find that an additional visit by a hospice costs around \$200, for-profits enjoy an efficiency advantage over non-profits, and hospices in rural counties face higher cost of making visits than those in urban counties.

Using the estimated demand and cost parameters, I solve for hospices' equilibrium quality choices under various counterfactual policies. My first set of counterfactuals involve the persistence of a hospice's reputation. A policy that increases the persistence of a hospice's reputation - for instance, a review website that centralizes information on quality provision - lead to significant improvements of a hospice's quality. My second set of counterfactuals involve Medicare's reimbursement rates for hospices. I find that firms choose higher quality as Medicare price increases, but a firm's response depends on how differentiated it is in terms of characteristics compared to its competitors. My third set of counterfactuals involve changing the reimbursement scheme structure for Medicare. I compare the current per-day

Medicare reimbursement scheme with a hybrid per-day and per-visit reimbursement scheme. The latter is found to achieve the same quality level at significantly lower cost.

I now give a brief discussion on how I model reputation in this paper. Instead of modeling reputation formation as a complex process of belief updating, I approximate the reputation stock of a hospice as a parametric function of its past quality choices. This reputation stock enters a consumer’s utility function and influences her choice of a hospice. This parametric approximation allows me to study reputation using only firm-level data and maintain computational tractability. It also allows me to be agnostic about the specific channel through which reputation operates. Consumers may care about reputation because quality is not contractible, or because reputation is a good statistic for predicting future quality in the face of bounded rationality, or alternatively because it lets consumers infer the underlying efficiency or altruism of the hospice. I discuss these issues in more detail in Section 5.

Related literature and contributions: I contribute to the empirical literature on reputation effects. To my knowledge I am the first to build and estimate a structural dynamic oligopoly model of reputation accumulation through quality choice. I also construct a novel way of measuring reputation using market share data. This is in contrast with other papers that measure reputation with user reviews; my approach has the advantage of not suffering from econometric issues involving user reviews while also allowing reputation to be studied in settings where such review data are not available. There is a large empirical literature on reputation effects, but in contrast to this paper most papers are centered around online platforms; an example is [Cabral and Hortag su \(2010\)](#) who document patterns around seller reputation on eBay. See [Tadelis \(2016\)](#) for an extensive overview. There is much less work on reputation outside online platforms; one such paper is [Jin and Leslie \(2009\)](#) who study hygiene quality and reputation incentives in the context of restaurants. They document evidence that indicate chains and non-chains have different reputational incentives, franchised units have an incentive to free-ride, and there is regional variation in reputation incentives. Even fewer papers attempt to analyze reputation acquisition via a structural model of firms. Apart from myself, two papers which do so are [Saeedi \(2019\)](#) and [Bai \(2022\)](#), and below I explain how my model and estimation are quite distinct from theirs.

Second, this paper contributes to the literature on quality choice of healthcare providers by showing the importance of reputation for patients choosing medical providers as well as medical providers choosing quality; I am not aware of other papers in the Economics literature documenting this result. Papers on healthcare provider quality include [Hackmann \(2019\)](#), [Lin \(2015\)](#), [Gaynor et al. \(2013\)](#), and [Wang \(2022\)](#). Like [Gaynor et al. \(2013\)](#), I also add to the literature on how healthcare providers choose quality in a regulated-price setting.

Third, I contribute to a very scarce literature on hospices. I am the first to structurally

estimate the supply-side of this industry. While healthcare providers like hospitals and nursing homes have been studied extensively, hospices have seen relatively little work in the Economics literature. Prior work on the hospice industry include [Chung and Sorensen \(2018\)](#), who estimate a nested logit demand model to examine market expansion through hospice entry.

As previously mentioned, two other papers that estimate a structural model of reputation are [Saeedi \(2019\)](#) and [Bai \(2022\)](#). [Saeedi \(2019\)](#) studies how eBay sellers choose quantity over time to qualify for Powerseller status or Registered-Store status. In contrast to my paper, her model assumes quality of sellers is exogenous and buyers are unaware of past buyers’ experiences. A seller wants to be a Powerseller/registered-store so as to signal to consumers, and these badges are the “reputation mechanisms” she studies in her paper. [Bai \(2022\)](#) studies watermelon sellers using an experiment where some watermelons are laser-branded as a costly signal of quality. Unlike my paper, she does not assume that consumers have accurate knowledge of a seller’s quality choice, neither does she assume that sellers can precisely choose their quality. Her demand model explicitly accounts for consumer learning and beliefs. Unlike me, she estimates a simplified supply side model of pricing and quality that does not account for competition, and given the lack of data cannot model long-term dynamics.

A strand of literature that this paper bears resemblance to is the advertising and brand management literature in marketing. Several structural papers in that field look at how firms spend money on advertising to build up their brand equity; see [Dubé et al. \(2005\)](#) and [Borkovsky et al. \(2017\)](#), and the references therein. This paper also adds to a broad literature on estimating dynamic games. I use the framework put forth in [Ericson and Pakes \(1995\)](#), and use estimation methods from [Bajari et al. \(2007\)](#) and [Pakes et al. \(2007\)](#). My paper has similarities with [Benkard \(2004\)](#), in that I use a nested-logit demand framework within a dynamic game of accumulation, as well as use similar model solution techniques. While my paper is about reputation accumulation, [Benkard \(2004\)](#) is about accumulating experience levels. Finally, this paper has similarities with the dynamic investment literature in industrial organization; classic references are [Olley and Pakes \(1996\)](#) and [Ericson and Pakes \(1995\)](#).

2 Industry background

Hospices provide palliative care to terminally ill patients, the majority of whom die within 1 week to 3 months in my sample. Patients who enroll in hospice typically no longer receive curative treatment. Most patients in the dataset are covered by Medicare, which reimburses

hospices a fixed amount for every day the patient is enrolled. In return, hospice staff provide care to their patient by visiting her at her residence. The number of visits a hospice makes to its patient is a good measure of the quality of service, and I claim that a hospice can build up its reputation over time by consistently providing higher quality over time.

2.1 Quality provision

Unlike other medical providers, hospices typically provide care at the residence of the patient, with different staff being responsible for different parts of care. Hospices employ several types of staff: registered nurses, licensed vocational nurses, home healthcare aides, physicians, social workers and chaplains. Of these, registered nurses, licensed vocational nurses and home healthcare aides (henceforth referred to altogether as hospice nurses) are responsible for the vast majority of patient visits. Physicians rarely make visits, and usually deal with reports on the patients from nurses. Social workers help the patient and her family with paperwork and choices, while chaplains make visits to a dying patient.

The hospice nurses make multiple visits to a patient over the course of a week throughout the enrollment period of the patient. Administrators of a hospice decide how many visits to make for each patient, and set up the schedule for each nurse. A day for a hospice nurse involves driving to several patients as determined by the administrator, giving them care, writing up reports for the hospice physician and administrator, and refilling supplies.

The care given by hospice nurses is relatively low-skill compared to other medical providers. Hospices are not responsible for curative treatment; they are tasked with pain management and ease-of-living for a dying patient. Examples of hospice care include administering pain medication, providing medical supplies like oxygen and bandages, dressing bedsores, giving physical and speech therapy, helping with bathing and feeding, temporarily substituting as the primary caregiver, tending to emotional and spiritual needs of the patient, and giving grief counselling to the family after the patient passes away.

Hospice nurses do not function as the primary caregiver of the patient - someone in the patient's residence (a family member if the patient resides at home, or a nurse if the patient resides in a nursing facility) has to be the primary caregiver. But hospice nurses assist the primary caregiver, and sometimes may substitute in for a period of time to give respite to the primary caregiver.

It is important to note that the hospice decides how many visits to make to each patient and what care is to be provided during each visit. As is explained below, the patient does not incur any additional cost for more visits, and so would ideally like as many visits as possible.

Medicare also distinguishes between different types of care; specifically, it draws a distinction between routine care (which is the care described above), inpatient care (where a patient moves to an inpatient ward of a hospice for intense treatment) and continuous respite care (where the hospice takes over as the primary caregiver). The majority of patients in my sample are given routine care.

2.2 Choosing a hospice

After a patient suffering from a terminal illness decides to no longer seek curative treatment, she and her family can choose to enroll into a hospice. How a hospice is chosen can vary. Sometimes a social worker at the hospital would give the patient a list of hospices, and suggestions on which to choose from past experience; the same can be done by the patient's physician. The family can also search for hospices online (aided by online reviews and forums), or can rely on word-of-mouth from other families that have needed hospice services in the past.

When looking for advice on how to choose a hospice, a few suggestions are common. One is to choose hospices that are reputable and have served the community well over a long time.² Another is to choose a hospice that makes regular visits, is readily available for emergencies, and is ready to give care to patients with various complexities and circumstances. Additional suggestions include asking how the hospice will co-manage with and give respite to the primary caregiver.

These suggest several things. First, reputation matters - a hospice which has provided high quality of care in the past is more likely to be suggested by social workers, better known in the community and better reviewed than a hospice which has not. Such a hospice is more likely to be selected by a patient and her family, and so will have greater market share. This also suggests how information about a hospice's past quality choices can persist over time. Second, quality of care is strongly dependent on the number of visits that a hospice makes to a patient. A hospice which makes more visits is constantly checking and adjusting to the patient's condition, can manage symptoms better, and is likely to arrive quickly in the

²Some websites which give suggestions on how hospices are chosen are listed in Appendix B.1 alongside relevant quotes. A representative quote from AmericanHospice.org reads:

"What do others say about this hospice? Get references both from people you know and from people in the field - e.g., local hospitals, nursing homes, clinicians. Ask anyone that you have connections to if they have had experience with the hospice and what their impressions are. Geriatric care managers can be a particularly good resource, as they often make referrals to hospices and hear from families about the care that was provided."

Similarly, HospiceFoundation.org states:

"Seek professional opinions. Ask clinicians, professional caregivers at nursing homes, geriatric care managers, or end-of-life doulas about their experience with a hospice. Talk to friends, family, and neighbors who have used hospice services and get their opinions about the experience with a provider."

case of an emergency. Such a hospice is also able to provide more respite to the patient’s primary caregiver, which may be highly valued by the family. It is also likely that number of visits is correlated with the general effort of the hospice, and so with other unobserved dimensions of quality. While the above suggest that reputation and number of visits are important determinants of hospice choice, I estimate a demand model to check if that is indeed the case.

One potential criticism is that number of visits as a measure of quality does not capture the content of the visit itself. For instance, what if there’s a hospice that makes many visits but does little per visit, while another hospice makes few visits but does a lot of useful work during each visit? Or what if one hospice trains its nurses better than another hospice? While these concerns might be relevant for other medical providers, for hospices they are less likely to be relevant. As explained above, hospice care is mostly low-skill care. The majority of it is giving pain medication, making adjustments to living arrangements, and helping out the patient with certain physical activities such as bathing. As such, it is unlikely that there will be great heterogeneity across hospices regarding what is done in a single visit for the same patient. In my demand model I do allow for persistent unobserved hospice quality, which can control for characteristics like well-trained and better behaved nurses, but my supply side does not endogenize this as part of the hospice’s choices.

2.3 Payers and reimbursement schemes

Hospice services can be paid for by Medicare, Medi-Cal (California’s Medicaid), private insurance, and various other payers. In my setting the overwhelming majority of patients are paid for by Medicare (see Table 1), and furthermore Medi-Cal’s reimbursement is essentially the same as Medicare’s. As a result, I focus my discussion on eligibility rules and reimbursement schemes for Medicare only.

For a patient covered by Medicare, hospice care is essentially free. There is no out-of-pocket cost for enrolling into or receiving visits from a hospice. Patients have to give a copay of up to \$5 for outpatient drugs required for pain management. This means that the “price” of choosing a hospice does not vary across hospices in the patient’s choice set, and moreover can be thought of as zero.

For the hospice, enrolling a patient covered by Medicare results in the hospice getting paid a fixed rate for every day the patient is enrolled (i.e. a per-diem rate). It is important to note that the fixed rate is set exogenously and does not depend on the number of visits that the hospice staff makes. To contrast extreme examples, if a patient enrolls in a hospice for 14 days, the hospice gets paid a fixed amount for each of those 14 days irrespective of

how many visits they make.

The Medicare rate is determined as follows. Medicare sets a national per-diem rate that is split into a “labor component” and a “non labor component”. Medicare also creates wage indices for each Metropolitan Statistical Area (MSA), such that a MSA with high wages will have a high wage index. The per-diem reimbursement rate of a hospice is the non-labor component and the labor component times the wage index of the hospice’s MSA.³

Medicare allows the per-diem rate to vary substantially based on whether the care provided is routine home care, inpatient care, or continuous care. Medicare also lowers the per-diem rate for routine care if a patient is enrolled for more than 60 days.

| Payer | % of patients |
|-------------------|---------------|
| Medicare | 83.7 |
| Medi-Cal | 7.37 |
| Private insurance | 6.37 |
| Selfpay | 1.65 |
| Charity | 0.82 |

Table 1: Percentage of total patients covered by each payer type.

3 Data

The dataset for this paper comes from firm-level data on hospices in California for 2002-2018. I use these data to construct firm-level measures of quality, defined to be average-visits-per-patient made by a hospice in a year. A market is defined to be at the level of a county, and I restrict my estimation to 28 counties. Total firms in a market range from 1 to 23, with moderate entry and little exit.

3.1 Data source

The main dataset comes from Home Health Agencies And Hospice Annual Utilization Reports compiled by California Department of Health Care Access and Information (CHAI). Hospices in California are required to submit yearly utilization reports to CHAI where they report firm-level statistics for the year. This includes measures such as current location, total

³To work out an example: for FY 2021, the labor component of routine home care is \$136.9, and the non-labor component is \$62.35. Suppose a hospice is in a county with a wage index of 0.8. The reimbursement rate of the hospice is approximately $136.9 \times 0.8 + 62.35 = \171.87 . See Appendix B.2 for an example Medicare’s reimbursement rates and its variation across counties.

number of patients, total visits per year (broken down by type of staff), hospice characteristics, aggregate characteristics of patient pool, etc. I collect and clean utilization reports of hospices for 2002-2018. I complement this with additional data sources on population sizes (by age), mortality rates, and Medicare hospice reimbursement rates for California over the same time period.

3.2 Market definition

A market is defined to be at the level of a county. While some hospices offer services to multiple counties, I can rule out clusters of counties as a market definition using data. Specifically, the dataset contains a breakdown of a hospice’s patient pool by patients’ counties of residence. Most of a hospice’s patients originate from the county where the hospice is located; more details are presented in Appendix ???. This is reasonable since both the hospice and the patient have a strong preference to minimize distance - the patient wants to be close to the hospice so that they can benefit from quick visits during an emergency, and the hospice prefers serving nearby patients since it is less costly to travel to their residences. The only exception are Yuba and Sutter counties which have a large overlap of patients, and so I combine them into a single market. Market size is constructed by multiplying the population size of each age bracket for a market with the corresponding mortality rate.

I focus on 28 counties for my project. While California has 58 counties, I have to drop the remainder for the following reasons. First, several counties do not see any hospice presence over the course of my dataset. Second, a few counties have a very large number of hospices (Los Angeles county has over 300). Markets with many small sellers have very different dynamics than those with few sellers. My model and estimation are oriented towards strategic interactions among small numbers of players and does not naturally accommodate such active markets.⁴ Having few firms in a market also allows me to disentangle the competitive effects of rivals very clearly. Such sample selection is in line with many dynamic oligopoly papers such as [Lin \(2015\)](#) and [Collard-Wexler \(2013\)](#); in fact, the highest firm count in my data is 23, which is considerably more than these papers.

3.3 Measuring quality

Following the discussion in Section 2.2, my measure of quality should reflect how often a hospice visits its patients. Recall that I have firm-level data; the dataset gives me total visits

⁴In the IO literature, markets with many small sellers have been modeled using the oblivious equilibrium of [Weintraub et al. \(2008\)](#). A separate paper by myself aims to study hospice entry and exit for these markets in California.

that a hospice makes to its entire pool of patients within a year and the number of patients it serves in the same year. Table 2 breaks down the ratio of total visits to patients for a hospice-year by staff type. It shows that nearly all visits are made by nurses and homemakers, and only these staff visits exhibit some variation across hospices and over time. Physicians and chaplains make very few visits, while social service workers seem to make a fixed number of visits across hospices. Therefore, I set my measure of quality to be the sum of nurse and homemaker visits divided by the number of patients. This is henceforth referred to as the average-visits-per-patient that a hospice makes in a year.

| | 10% | 25% | 50% | 75% | 90% |
|----------------------------|-------|-------|-------|-------|-------|
| Registered nurses | 8.82 | 11.42 | 14.44 | 18.21 | 22.48 |
| Licensed vocational nurses | 0.0 | 0.0 | 0.64 | 4.43 | 8.9 |
| Homemakers | 5.39 | 7.69 | 11.24 | 16.85 | 24.21 |
| Physicians | 0.0 | 0.0 | 0.01 | 0.25 | 0.77 |
| Social service workers | 1.74 | 2.59 | 3.55 | 4.73 | 6.05 |
| Chaplains | 0.27 | 1.02 | 1.84 | 2.87 | 4.08 |
| RN + LVN + Homemakers | 17.17 | 21.88 | 27.83 | 37.66 | 52.48 |

Table 2: Distribution of visits by staff type for each hospice-year. The unit is visit per patient.

3.4 Summary statistics on competition and patients

I now present some summary statistics on competition and patient composition within my sample. The tables below and in the Appendix show distributions of various key variables; the main takeaways are as follows. First, the vast majority of hospices have over 100 patients. This assuages worries that my key measure of quality - average visits per patient- is mostly driven by patient severity, since we would expect that variations in patient severity would even out over a large number of patients over the course of the year. Second, the median firm count is 2 with the 75th percentile at 4, suggesting that an oligopoly setting is the correct mode of analysis instead of perfect competition. Third, while the total entry and exit over the 16 years of my data is significant, there is very little turnover in a market within an individual year. In my model, I will treat exit as effectively exogenous due to the lack of variation in my data. Fourth, the vast majority of patients have a length of stay between a week and 3 months. Finally, Appendix A does a breakdown of patients by diagnosis, revealing that roughly half the patients are suffering from cancer.

Finally the data contains information on hospice-specific services and characteristics. These vary substantially across hospices, although there is little variation within a hospice

| | Min | 10% | 25% | 50% | 75% | 90% | Max |
|-------------|-----|-----|-----|-----|-----|-----|------|
| firm count | 1.0 | 1.0 | 1.0 | 2.0 | 4.0 | 7.0 | 23.0 |
| entry count | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 5.0 |
| exit count | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 3.0 |

Table 3: Distribution of market-level characteristics. Each observation is at the county-year level.

| | 10% | 25% | 50% | 75% | 90% |
|--------------|------|-------|-------|--------|-------|
| patients | 63.0 | 149.0 | 289.5 | 511.75 | 765.0 |
| market share | 1.41 | 3.6 | 8.53 | 18.5 | 37.0 |

Table 4: Distribution of patients and market share. Each observation is at the hospice-year level.

over time. To give a snapshot, in 2017 there were 171 hospices in my dataset; of these, 12 had an inpatient unit, 15 offered special pediatric services, 2 offered adult day care services, and 95 were for-profit. The dataset also breaks down hospices by agency type: 110 hospices were free-standing, 27 also had a home-health unit, and 31 were hospital-based. I control for these characteristics in my demand estimation.

4 Structural model

To study and model reputation in this setting, I set up a structural model of demand and supply for the hospice industry. The demand side is a discrete-choice model that incorporates a measure of reputation of the hospice. The supply side is a dynamic oligopoly model where forward-looking hospices are choosing quality in a competitive setting. The remainder of the section details the equilibrium concepts and the timing of the dynamic game, and concludes with a discussion on reputation in my model.

4.1 Demand

The demand for hospices is modeled as a nested-logit discrete choice model, with a nest on hospices. A consumer can choose between any hospice present in the market in that period, or an outside option. The outside option of not choosing a hospice can be interpreted as the consumer continuing intense curative treatment, or choosing to be cared for by family/nursing home staff.

The utility of consumer i from choosing hospice j in period t is given by:

$$u_{ijt} = \alpha_{m(j)} + X'_{jt}\beta + \psi_{jt} + \xi_{jt} + \zeta_i + (1 - \sigma_n)\tilde{\epsilon}_{ijt} \quad (1)$$

$$\xi_{jt} = \rho\xi_{jt-1} + \epsilon_{jt} \quad (2)$$

where $m(j)$ denotes the market in which hospice j is present and X_{jt} represents hospice characteristics⁵. The term ξ_{jt} denotes unobserved hospice-specific quality that is allowed to be serially correlated and vary over time. This can reflect factors like how connected the hospice is with physicians/nursing homes, advertising, and care quality beyond number of visits. The term ψ_{jt} is the reputation stock of hospice j in time t . Finally, $\zeta_i + (1 - \sigma_n)\tilde{\epsilon}_{ijt}$ reflect that this is a nested logit - there are two nests, one on all hospices and one on the outside option.

Reputation effect is incorporated as a stock transition equation:

$$\psi_{jt} = (1 - \tau)\psi_{jt-1} + \eta a_{jt} \quad (3)$$

where a_{jt} is the average number of visits made by hospice j in period t . Assuming $\psi_{j0} = 0$ (i.e. a new entrant has a reputation of zero), this can be rewritten as:

$$\psi_{jt} = \eta[a_{jt} + (1 - \tau)a_{jt-1} + (1 - \tau)^2a_{jt-2} + \dots]$$

That is, a firm's reputation is a discounted sum of its past choices of quality. I now offer a more thorough discussion on the modeling choices.

First, the nest on hospices (i.e. the inside options) allows for more flexible substitution patterns between hospices and the outside option relative to a simple logit with no nests. For instance, a high value of the nest parameter implies that should a consumer decide not to pick hospice j_1 , she is more likely to pick another hospice j_2 instead of switching to the outside option; i.e. a consumer's preferences are positively correlated within the nest.

Second, the persistence of unobserved hospice-specific quality ξ_{jt} allows me to capture persistent unobservables in demand. One example could be that a hospice is well-connected with physicians and social workers in particular hospitals and so get repeated referrals despite not choosing higher quality - this will manifest itself as the hospice having a high ξ_{jt} for many periods. Another example could be a hospice that has suffered a recent scandal such as elder abuse. Despite choosing high average visits-per-patient the negative publicity may last for

⁵The hospice characteristics are dummy variables for the following: hospice inpatient unit, pediatric program, bereavement services, day care for adults, for-profit status, free-standing hospice, home-health-based hospice, and hospital-based hospice.

several periods - this will manifest itself as the hospice having a low ξ_{jt} for many periods. Finally, this allows for the possibility that a hospice with high ξ might face less entry threat because it is more difficult to compete against. In the demand estimation this means I build moments around ϵ_{jt} instead of ξ_{jt} ; this follows [Grennan \(2013\)](#) and [Lee \(2013\)](#). The reasons behind why this is a more reasonable exclusion restriction are explained in [Section 6.1](#).

4.2 Per-period profit and marginal cost function

The cost to a hospice for serving a patient depends on its quality choice, cost type and other characteristics. I impose the cost to be increasing linearly in the level of average-visits-per-patient.

The cost of serving each patient at quality a_j (henceforth referred to as marginal cost) is given by:

$$MC_j(a_j) = \gamma_0 + \left(\gamma_{1k} + \gamma_{fp}FP_j + \gamma_{rural}RURAL_j \right) a_j$$

where the terms in the bracket reflect the slope of the marginal cost function. The slope depends on 3 factors, and the economic intuition is that hospices with flatter slopes can raise quality and incur a smaller increase in cost per patient. The first term γ_{1kj} reflects a firm's cost type - a firm with a better cost type has a smaller γ_{1k} and so a flatter marginal cost function. This reflects variations in efficiency and altruism across hospices. In my baseline specification all firms have the same type; I also estimate an alternative specification where firms can be one of two types. The second term γ_{fp} allows the slope of for-profits to differ from those of non-profits. This is meant to capture systematic differences in efficiency and altruism across for-profits and non-profits. The last term γ_{rural} allows rural hospices to have different cost than urban hospices; anecdotal evidence suggests that rural visits are more costly because of worse infrastructure and longer driving distances.

I set up the per-period profit function and cost function of the firms, subject to quality choice, firm attributes and market characteristics. A period is defined to be a year, and throughout the time subscript is suppressed for clarity.

Combining the demand function with fixed Medicare prices and market size, the per-period profit of a hospice j in market m choosing quality a_j is:

$$\bar{\pi}(a_j, \mathbf{a}_{-j}, \mathbf{x}_m; \theta) = M_m s_j(a_j, \mathbf{a}_{-j}, \mathbf{x}_m) [P_m^{MCAR} - MC_j(a_j)] \quad (4)$$

where \mathbf{x}_m denotes the state variable in market m , \mathbf{a}_{-j} denotes the vector of realized actions

of all rival firms in the market, and M_m is the market size.⁶ The price-per-patient P^{MCAR} is calculated as the Medicare per-day rate for that period multiplied with the average length of stay of a patient in the data (60 days). This gives the predicted revenue that a single patient generates for a hospice given that period's Medicare price.

For the demand side estimation I use the continuous measure of quality choice; however for estimating the supply side, I discretize quality choices into six tiers. This has the advantage of improving computational tractability (especially regarding counterfactuals) while still being a meaningful improvement of quality.

4.3 Dynamics of quality choice and entry

The above demand and per-period payoff functions are incorporated into a dynamic oligopoly model to understand how hospices choose quality over time and how potential entrants make entry decisions. Both these categories of firms are modeled together in the framework of [Ericson and Pakes \(1995\)](#).

The dynamic oligopoly is modeled as a discrete-time simultaneous-move game over an infinite horizon. Every period the incumbents decide what level of quality to provide. All consumers of a hospice receive the quality level chosen. Persistence of reputation means that current quality choices affect future sales, hence a forward-looking model is required; hospices also make this decision in a competitive setting, hence a model of strategic interaction is needed.

The incumbent's value function is:

$$V_j(\mathbf{x}_m, \epsilon_j^a; \theta) = \max_{a_j \in \mathcal{A}} \mathbb{E} \left[\bar{\pi}(a_j, \mathbf{x}_m; \theta) + \epsilon_j^a(a_j) + \beta V_j(\mathbf{x}'_m, \epsilon_j'^a; \theta) \middle| a_j, \mathbf{x}_m \right] \quad (5)$$

where θ is the set of structural parameters affecting a hospice's per-period payoff, ϵ_j^a is a

⁶This requires calculating market share of all firms for a given state \mathbf{x}_m . This is done using the analytical formulae for nested logit. Let

$$\delta_{jt} = \alpha_m + X'_{jt}\beta + \sigma_n \ln(s_{j|gt}) + \psi_{jt} + \xi_{jt}$$

where σ_n is the nest parameter that captures correlated preferences within the nest. Then the market share can be written as:

$$s_j(\boldsymbol{\delta}, \sigma_n) = \bar{s}_{j/g}(\mathbf{s}, \sigma_n) \bar{d}_g(\boldsymbol{\delta}, \sigma_n) = \frac{e^{\delta_j/(1-\sigma_n)}}{D_g^{\sigma_n} \left[\sum_g D_g^{(1-\sigma_n)} \right]}$$

where

$$D_g \equiv \sum_{j \in G_g} e^{\delta_j/(1-\sigma_n)}$$

vector of choice-specific errors for hospice j , and $\epsilon_j^a(a_j)$ is the choice-specific errors for hospice j choosing action a_j . The choice-specific error terms are meant to capture unobservables affecting a firm's quality choice. In keeping with the literature and to help with tractability in estimation, I assume these shocks to be *i.i.d* and distributed Type-1 Extreme Value.

There is a stream of short-lived potential entrants for each market and in every period. In a given period, a potential entrant observes the current industry state x_m and then chooses to either enter a market or disappear forever with a payoff of zero. Entry is implemented next period, i.e. a potential entrant choosing entry in period t joins the market in period $t + 1$. As a result, the potential entrant's value function is :

$$V_j^e(\mathbf{x}_m, \kappa_e; \theta) = \max_{\{out, enter\}} \left\{ 0, -\kappa_e + \epsilon^e + \beta \mathbb{E}[V_j(\mathbf{x}'_m; \theta) | \mathbf{x}_m] \right\} \quad (6)$$

where κ_e is the entry cost and ϵ^e is choice-specific structural error.

4.4 State transitions

In any period, the industry state comprises common-knowledge variables (own characteristics, rival characteristics, market characteristics) and private information (choice-specific structural errors ϵ^a). The industry state evolves due to a mix of firm decisions and exogenous transitions; below I list the assumptions I make on state transitions. The list of state variables and how their transitions are implemented during estimation are detailed in Section 6.2.1. The following mirrors the discussion in [Lin \(2015\)](#).

Let the vector of common knowledge state variables in the current period be \mathbf{x} . The vector of common knowledge state variables and private information is denoted as $\mathbf{s} = (\mathbf{x}, \epsilon^a)$. The state-to-state transition probability is $F(\mathbf{s}' | \mathbf{s}, \mathbf{a})$, where \mathbf{a} denotes the vector of firm choices in the current period. Following [Rust \(1987\)](#), I make two assumptions on the state vector:

1. Additive Separability: This imposes that the choice-specific structural error ϵ^a enters the per-period payoff function additively, i.e. $\bar{\pi}(a_j, \mathbf{x}_m, \epsilon_j^a; \theta) = \bar{\pi}(a_j, \mathbf{x}_m; \theta) + \epsilon_j^a(a_j)$. This assumption was already made when writing out the incumbents' value function.
2. Conditional Independence: This comprises two assumptions. One, \mathbf{x}' is independent of ϵ^a after conditioning on (\mathbf{x}, \mathbf{a}) . Two, ϵ^a is *i.i.d.* and evolves independently of other state variables. Mathematically, this can be written as:

$$F(\mathbf{s}' | \mathbf{s}, \mathbf{a}) = F(\mathbf{x}', \epsilon^{a'} | \mathbf{x}, \epsilon^a, \mathbf{a}) = F(\mathbf{x}' | \mathbf{x}, \mathbf{a}) F_\epsilon(\epsilon^{a'})$$

where $F_\epsilon(\cdot)$ denotes the distribution of ϵ^a .

4.5 Equilibrium and Conditional Choice Probabilities

This section describes the equilibrium concept used and how that leads to the conditional choice probabilities (CCPs) predicted by the model. These CCPs will later be matched to observed probabilities to estimate the cost parameters. For this subsection, the notation for parameters is suppressed from the arguments for clarity.

I focus on pure-strategy symmetric Markov Perfect Equilibrium (MPE). Each firm's strategy thus depends only on the observed state variable and its private choice-specific shocks. Therefore a firm's strategy can be written as a mapping from states and choice-specific shocks to actions:

$$\sigma_j : (\mathbf{x}_m, \epsilon_j^a) \rightarrow \mathcal{A}$$

Let the vector $\sigma = \{\sigma_j\}_{\forall j}$ denote the strategy profile of all firms in a market. I now show how this can be used to construct CCPs.

The choice-specific value function of action a in state \mathbf{x}_m , $W_j(a, \mathbf{x}_m)$, is the net payoff to the hospice j from choosing action a before choice-specific shocks ϵ_j^a are observed. The ex-ante value functions $V_j(\mathbf{x}_m; \theta)$ can thus be written in terms of choice-specific value functions:

$$\begin{aligned} V_j^\sigma(\mathbf{x}_m) &= \int V_j^\sigma(\mathbf{x}_m, \epsilon_j^a) dG(\epsilon_j^a) \\ &= \int \max_{a_j \in \mathcal{A}} \{W_j^\sigma(a_j, \mathbf{x}_m) + \epsilon_j^a(a_j)\} dG(\epsilon_j^a), \end{aligned} \tag{7}$$

The MPE is the strategy profile σ^* such that every firm is choosing the optimal strategy given the strategies of their rivals:

$$\sigma_j^*(\mathbf{x}_m, \epsilon_j^a) = \arg \max_{a_j \in \mathcal{A}} \{W_j^{\sigma^*}(a_j, \mathbf{x}_m) + \epsilon_j^a(a_j)\} \tag{8}$$

where the superscript σ^* indicates that the choice-specific value function is conditional on the optimal strategies of all the players.

Given this optimal strategy profile, the CCP of an action a_j taken by firm j can be written as:

$$\Psi(a_j | \mathbf{x}_m, \sigma^*) = \frac{\exp \{W_j^{\sigma^*}(a_j, \mathbf{x}_m) / \sigma_e\}}{\sum_{a \in \mathcal{A}} \exp \{W_j^{\sigma^*}(a, \mathbf{x}_m) / \sigma_e\}} \tag{9}$$

where σ_e is the scale coefficient of the Type-1 Extreme Value logit error ϵ^a .

4.6 Timing and state variables

Given the model above, the game’s timing is as follows. For period t and market m :

1. Incumbents observe \mathbf{x}_{mt} and all structural errors, and each make quality choices.
2. Reputation stock of each incumbent evolves.
3. Consumers observe \mathbf{x}_{mt} , reputation stocks, and structural errors, then choose a hospice.
4. Incumbents stay or exit the market.
5. Potential entrants observe \mathbf{x}_{mt} and decide whether to enter or disappear.
6. All state variables evolve.

5 Discussion

I now offer a more thorough discussion on how reputation operates in my model and explain the motivations behind the reputation transition equation.

In my model hospices are competing against each other for consumers, and each consumer makes a discrete choice of which hospice to pick. I assume hospices have complete information about each other, i.e. they know each others’ characteristics, types and past shocks. This is a reasonable assumption to make in my setting, because it is easy to imagine that hospices are carefully tracking their competitors over time. This means hospices do not use past choices of their rivals’ to make inferences over anything. However, consumers do care about a hospice’s reputation. Holding everything constant, a consumer is more likely to choose a hospice with high reputation over one with low. Given that this is the case, hospices have an incentive to persistently choose high quality over time and build up their reputation to attract consumers.⁷

Given this setting, why do consumers care about a hospice’s reputation? A few reasons are:

1. A hospice with higher reputation has more goodwill and recognition in the community, and so is more likely to be referred to the patient. This has parallels with the intangible brand capital literature - for example [Bronnenberg et al. \(2022\)](#) talks at length about

⁷Using the terminology from the theoretical literature on reputation, I am using a hidden action model of information (as opposed to hidden information). Hidden action models assume that quality is chosen by the firm and consumers try to predict a firm’s quality choice with full information about its past choices. In contrast, a hidden information model assumes that a firm’s quality is exogenously fixed, and the firm can choose to signal this quality type to consumers.

brand equity and reputation, and how these create an incentive for firms to repeatedly supply high quality over time. It also has parallels with reputation in a repeated game of quality choice under complete information.

2. To predict quality choice, consumers can track a firm's reputation alone instead of all possible state variables. As can be seen in the model above, quality choice is affected by factors such as unobserved demand shocks and hospice characteristics, all of which vary over time. Instead of keeping track of all these variables and their evolution, consumers can use reputation as a sufficient statistic of sorts.

Here is an example to clarify this further. Suppose a hospice has gotten a large positive demand shock in the recent past. Since demand shocks are persistent, this means the hospice will likely get high demand shock this period too. These demand shocks will influence the quality choice of the hospice; maybe the hospice chooses low quality since it is experiencing a bump in its demand through the shocks that will last for a while. Suppose also that the hospice had very favorable characteristics (X_{jt}) in the past that are likely to persist into the present period. Such characteristics will also influence the hospice's quality choice. Instead of keeping track of all these characteristics and shocks across hospices and over time, a consumer can just keep track of their past quality choices, which will contain the information from these persistent factors already. It might also be easier to keep track of reputation (by asking others about their impression of a hospice's recent performance) than something like demand shocks. It is also likely that demand shocks and hospice characteristics that aren't relevant to a patient's needs are observed with noise by that consumer, and so is even harder to track. Such information can also disappear or become harder to acquire with time.

3. A hospice with higher reputation may have persistently low cost or high altruism. In contrast to the above two explanations where hospices had the same cost function, suppose it were the case that hospices have differences in cost. This variation in cost can come from greater efficiency or altruism. Hospices can thus be of different types, and these types are unobserved by consumers. In this setting, consumers will use reputation to infer a hospice's type. A hospice which has high reputation has consistently chosen high quality in the past, and may have persistently low cost (i.e. is high type). Such a high type hospice is more likely to provide high quality in the current period. There is an extensive theoretical literature on consumers using reputation to learn about the firm; see [Fudenberg and Tirole \(1991\)](#) for more details.

Another element of the model is that reputation depreciates at the rate of τ . This raises the question - why does reputation depreciate? There are several possibilities. One,

information on quality choices disappears over time. This might be because of forgetting by the community. It could also be due to retirement or relocation of physicians, social workers, and community members. The patient’s family is less likely to require a hospice soon after the patient passes away, so the fact that there are no repeat consumers (unlike online platforms) means information is less likely to persist. Another way of thinking about this is that information on past choices is still available but gets more costly to retrieve over time. Two, past quality choices may be less relevant over time. This is because past quality choice also represents old and outdated medical practice styles, technology, and medicine. An example is that a hospice nurse’s visit 20 years ago had very different content compared to a hospice nurse’s visit at present. Third, quality choices very far in the past reflect the hospice’s demand shocks and characteristics that may no longer have any predictive power, since these are also changing over time.

Finally, note that my reputation transition equation includes current visit as well as past visits. This means that current period reputation - which influences hospice choice by a consumer - is affected by current quality choice. This seems to indicate that consumers observe current quality choice; if so, why would they need to predict current quality choice using past choices? First, I also estimate demand using a reputation transition equation that does not contain current visit and still find strong presence of reputation. Second, the decision to include current quality into reputation is mainly driven by the fact that my data is at the yearly level. This means information on current quality choice has time to diffuse through the community over the course of a year. Finally, it accounts for the possibility that a hospice might be able (to some extent) to convince a potential consumer about the level of quality they will provide.

6 Estimation strategy

This section details how the structural model above is estimated. The demand model is estimated using two-stage GMM following the inversion technique of [Berry \(1994\)](#). The supply side is estimated using the two-stage simulation method of [Bajari et al. \(2007\)](#) that matches simulated choices with observed choices.

6.1 Demand estimation

Using [Berry \(1994\)](#), the nested-logit discrete choice model can be rewritten in terms of market shares:

$$\ln(s_{jt}) - \ln(s_{0t}) = \alpha_m + X'_{jt}\beta + \sigma_n \ln(s_{j|gt}) + \xi_{jt} + \eta[a_{jt} + (1 - \tau)a_{jt-1} + (1 - \tau)^2 a_{jt-2} + \dots]$$

where s_{jt} and s_{0t} represent the market shares of hospice j and the outside option respectively, and $s_{j|gt}$ is j 's within-hospice market share. Recall that for flexibility we also allow the unobserved demand shocks to be persistent:

$$\xi_{jt} = \rho \xi_{jt-1} + \epsilon_{jt}$$

These equations are estimated simultaneously via two-step GMM. Endogeneity is an issue since the within-hospice market share $s_{j|gt}$ is mechanically correlated with unobserved demand shock ξ . Besides, it is likely that choice of visits is also correlated with ξ . As a result, I use instruments from [Berry et al. \(1995\)](#) (henceforth BLP IVs) and fuel prices. BLP IVs are standard instruments in the IO literature that use measure of competitiveness in product space to create variation in within-hospice market share and quality choice while being orthogonal to ϵ_{jt} in the ξ transition equation. In my setting, these are the sum of rivals and sums of various rival characteristics. Fuel prices are cost shifters that also cause the same variation while being orthogonal to ξ . These instruments are multiplied with the error term ϵ_{jt} to give moment conditions for GMM.⁸

It is now clearer to see why building moments around ϵ_{jt} is giving me a better exclusion restriction. Without it, I would have to assume that level of competition in the market is orthogonal to the ξ of all incumbents. But that might not be true - if the incumbent has persistently high (or low) ξ , then that could affect entry/exit decisions and hence the level of competition in the market. By allowing for persistence, the claim is that level of competition is orthogonal to some residual term after accounting for persistence.

6.2 Dynamic oligopoly model

The two-stage estimator from [Bajari et al. \(2007\)](#) is used to estimate the cost parameters. The first stage involves getting reduced-form estimates of the firms' policy functions from the data, as well as state transition estimates for state variables. In the second stage, these policy functions are used to conduct forward simulation and generate model-predicted CCPs for a

⁸This requires estimating a large number of parameters, including county fixed effects and coefficients on hospice characteristics. A trick to easing computational burden is to note that only τ and ρ enter nonlinearly, so I can concentrate out all the linear parameters and minimize over (τ, ρ) .

given guess of cost parameters. Moment conditions are then constructed, and an optimizer searches to find cost parameter values that minimize the distance between model-predicted CCPs and observed probabilities.

6.2.1 Policy functions and state transitions

Transition of state variables: The state variables that enter a firm’s value function are its characteristics and unobserved shocks, its rivals’ characteristics and unobserved shocks, its lagged reputation, its rivals’ reputations, Medicare rates, the share of its patients who are served at home or who are expected to stay over 180 days, market size, and identity of the county where it operates. Below I explain how I implement state transitions in my forward simulation.

For the estimation, I assume that a firm’s characteristics do not change over time; this assumption matches observed patterns in the data. Firms’ current period unobserved shocks are imputed from the demand estimation; the estimated persistence is used to simulate it forward while drawing the errors from the econometric error distribution. Market size and Medicare rates follow an AR(1) process that is estimated from the data. Share of patients at home or staying over 180 days are drawn from the empirical distribution.

Firm types: Persistent firm-specific heterogeneity can affect quality choice. For instance, a hospice can be more altruistic or efficient than its rivals, causing it to choose higher quality than would be predicted by the competitive environment in which it resides. To account for this, I run a regression of visit choices on hospice fixed effects, hospice characteristics and market characteristics.⁹ The fixed effects can then be interpreted as how much the firm deviates from the level of visits that would be predicted by the competitive environment. These hospice-specific fixed effects are divided into 2 tiers; hospices with fixed effects in the first or second tier are called type 1 and 2 respectively. The intuition is that a hospice of a higher type is more efficient or altruistic, and so chooses higher quality than a hospice of a lower type in the same competitive environment. In one specification of my dynamic oligopoly estimation, I allow marginal cost to vary by hospice type; *a priori* a hospice of a higher type has lower marginal cost.

This now raises the question of what it means, in an economic sense, to have a higher type. In the previous paragraphs a higher type has been ascribed to greater efficiency (hospice’s cost primitive) or greater altruism (hospice’s preference primitive). Ideally the hospice’s objective function will contain an “altruism” term that accounts for the hospice

⁹The regressors include: rivals’ reputation tiers, functions of rivals’ characteristics, rivals’ imputed demand shocks, own reputation stock, own characteristics, aggregate data on lengths of stay of own patients, share of patients who reside in their own home, firm age, share of patients with cancer, Medicare price, market size and fuel prices. Fixed effect of firms vary from -2 to 65; I set 33 to be the cutoff for type.

| | No types | Time invariant |
|---|-------------------|-------------------|
| ξ_{jt} | -0.843 (0.114) | -0.996 (0.117) |
| $X'_{jt}\beta$ | 0.355 (0.566) | -1.285 (0.589) |
| Own reputation | 2.902 (0.203) | 2.997 (0.209) |
| Count of rivals in first reputation tier | 0.214 (0.057) | 0.207 (0.058) |
| Count of rivals in second reputation tier | 0.244 (0.042) | 0.245 (0.042) |
| Count of rivals in third reputation tier | 0.081 (0.028) | 0.084 (0.029) |
| For-profit | 1.315 (0.215) | 0.521 (0.226) |
| Share of patients with 180+ days stay | 0.167 (0.012) | 0.178 (0.012) |
| Share of patients with home residence | -0.020 (0.003) | -0.016 (0.003) |
| Type 2 | | 1.649 (0.128) |

Table 5: Ordered logit estimates of visit-choice policy function. County fixed effects and cutoffs suppressed. Average visits-per-patient discretized into 6 bins of 0-15, 15-22, 22-29, 29-36, 36-43, and 43+ with open lower intervals and closed upper intervals.

caring about patient well-being irrespective of profits, and the marginal cost function will be heterogeneous across hospices. However, in my model an efficient versus an altruistic hospice behave similarly (they both choose higher quality than expected), and so it is not possible to distinguish between efficiency and altruism in my model. Instead, I assume that the hospice maximizes profits, and allow the marginal cost to vary by type; the caveat being that a higher type is either more efficient, or its greater altruism is causing it to behave as *if* it is more efficient.

First-stage policy function: For the first stage of the [Bajari et al. \(2007\)](#) estimation method, I get an empirical estimate of the policy function by projecting visit choice on state variables. The visit choice is discretized into six tiers, and an ordered logit is estimated. The results are given in Table 5.

Entry and exit: Entry and exit are quite infrequent in my data, so I implement entry and exit as exogenous transitions rather than endogenizing them as part of the firm's choice problem. In my forward simulation, entry by potential entrants into a market is modeled

| | Entry count |
|----------------|---------------------------|
| Firm count | -0.300 (0.117) |
| Market size | 0.001 (3.461e-04) |
| Medicare price | -3.846e-04 (2.423e-04) |
| County FE | Yes |

Table 6: Entry count transition function. County FE and cutoffs suppressed. Ordered logit on entry counts of 0, 1, 2 and 3 across market-by-year observations.

through an ordered logit specified in Table 6. Exit by a firm happens with a probability of 4% every period, which matches exit rates in my data.

6.2.2 Second-stage

In the second stage, these first-stage policy functions and transition matrices are used in forward simulation. Given a guess of structural parameters θ , for every state variable \mathbf{x}_t the forward simulation is used to derive the choice-specific value function $W(a_j; \mathbf{x}_t, \theta)$. These choice-specific value functions are used to construct predicted choice probabilities from the structural model. The optimizer then searches over the parameter space to find values that minimizes the distance between predicted choice probabilities and observed choices.

6.2.3 Objective function

The dynamic oligopoly model is estimated using two-step GMM. The model-predicted error term for observation n is given by:

$$\Xi_n(\theta) = a_n^{data} - \sum_{a_n \in \mathcal{A}} a_n \hat{\Psi}(a_n | \mathbf{x}_{mt(n)}^{data}, \theta)$$

where $\hat{\Psi}(a_n | \mathbf{x}_{mt(n)}^{data}, \theta)$ is the predicted choice probability for action a_n , θ is the guess of structural parameters, $mt(n)$ denotes the market-by-year that observation n occupies, and the superscript *data* indicates that the value of the variable comes from the data. The error term measures how close the average model-predicted choice is to exactly predicting the observed choice. The instruments used in GMM are the variables in the first-stage empirical policy functions, giving us the moment conditions $E[Z'\Xi_n(\theta)]$. The intuition for this is that the model's predicted choices leverage the variables in the first-stage policy functions, and so at the true parameter values the model's prediction errors should be orthogonal to these

variables. The objective function for the population is:

$$\min_{\theta} E \left[Z' \Xi(\theta) \right]' W E \left[Z' \Xi(\theta) \right]$$

The empirical version averages the moment conditions over observations, giving us the implementable formula:

$$\min_{\theta} \left[\frac{1}{N} \sum_n Z'_n \Xi_n(\theta) \right]' \hat{W} \left[\frac{1}{N} \sum_n Z'_n \Xi_n(\theta) \right]$$

This objective function is minimized to estimate cost parameters of hospices. Standard errors are calculated via block-bootstrapping. I sample blocks of county-year observations from my data with replacement until I match the total number of county-year observations in my dataset. Then I re-estimate the model on each bootstrap sample. The sample variance over all the resulting bootstrap estimates gives me the standard errors for my cost parameters. This closely follows [Wang \(2022\)](#).

7 Results

Table [7](#) shows the results from the demand estimation. The reputation decay rate τ is estimated to be 0.53, which can be interpreted as saying 47% of a hospice's reputation transfers over to the next year. A positive value of η means that an increase in hospice's quality choice leads to an increase in reputation. The unobserved shocks are highly persistent (ρ), and consumer preferences within a nest are highly correlated (σ_n). The remaining values in Table [7](#) gives consumer preferences for hospice characteristics.

Table [8](#) gives the results of the dynamic supply estimation. The marginal cost should be interpreted as the cost per patient over their entire stay at a specified quality level; for instance, $MC(a_j = 30)$ gives the cost per patient when giving 30 visits to each patient. The estimation is done for two specifications, with and without cost types. Recall that for the dynamic supply estimation, the quality choices are discretized into 6 bins, each separated by roughly 7 visits. As a result, γ_a should be interpreted as the increase in marginal cost for 7 additional visits. Across the two specifications the marginal cost of an additional visit is approximately \$191-220. For-profits enjoy an efficiency advantage worth \$76-105 per visit. Hospices operating in rural markets suffer from a cost disadvantage of \$17-29 per visit. For the specification with cost-types, type-2 hospices enjoy a cost advantage of \$84 per visit over type-1 hospices.

I perform additional robustness checks not reported in the main text. Alternative demand

| | Demand |
|--------------------------------|-------------------|
| τ | 0.530 (0.156) |
| ρ | 0.756 (0.072) |
| σ_n | 0.597 (0.034) |
| η | 0.012 (0.003) |
| Hospice inpatient unit | 0.011 (0.112) |
| Pediatric program | 0.223 (0.071) |
| Bereavement services | 0.008 (0.037) |
| Day care for adults | 0.038 (0.169) |
| For-profit | -0.291 (0.081) |
| Agency type: free-standing | -0.168 (0.133) |
| Agency type: home health based | -0.287 (0.152) |
| Agency type: hospital-based | -0.259 (0.159) |

Table 7: Results of demand estimation

| | No types | With cost-types |
|------------------|--------------------------|--------------------------|
| γ_1 | 1343.728 (32.311) | 1541.100 (48.872) |
| γ_{fp} | -740.676 (93.892) | -532.156 (116.642) |
| γ_{rural} | 125.534 (54.289) | 206.063 (74.825) |
| σ_e | 5.018e+05 (95866.721) | 3.419e+05 (1.307e+05) |
| γ_{12} | | -594.847 (111.097) |

Table 8: Results of supply estimation

specifications with firm fixed effects give very similar results. Impact of a firms' age is already subsumed in my reputation transition equation (a firm who has lived longer has a larger

number of quality choices affecting its current reputation), but a demand specification that includes age as a hospice characteristic also finds presence of reputation effects. I re-estimate the demand model without allowing current quality choice to enter reputation this period finds presence of reputation effects as well. Finally, I estimate the marginal cost but allow firms to switch types exogenously over time, and get similar results as well.

8 Counterfactuals

Given the above estimates of the structural parameters, I can now conduct counterfactuals to investigate the effects of various policy environments.

8.1 Counterfactual estimation

To conduct counterfactuals I need to fully solve the model. This requires solving a nested fixed-point problem; more specifically, I need to calculate $\Psi(a_j|\mathbf{x})$, $\hat{v}(a_j, \mathbf{x})$ and $V(\mathbf{x})$ such that all 3 of the following equations simultaneously hold:

$$\Psi(a_j|\mathbf{x}) = \frac{e^{\hat{v}(a_j, \mathbf{x})/\sigma_e}}{\sum_{a \in \mathcal{A}} e^{\hat{v}(a, \mathbf{x})/\sigma_e}} \quad (10)$$

$$\hat{v}(a_j, \mathbf{x}) = \sum_{\mathbf{a}_{-j} \in \mathcal{A}_{-j}} \left\{ \left[\bar{\pi}(a_j, \mathbf{a}_{-j}, \mathbf{x}') + \beta V(\mathbf{x}') \right] F(\mathbf{x}'|\mathbf{x}, a_j, \mathbf{a}_{-j}) \prod_n \Psi(\mathbf{a}_{-j}[n]|\mathbf{x}) \right\} \quad (11)$$

$$V(\mathbf{x}) = \sigma_e \left[0.577216 + \ln \left(\sum_{a_j \in \mathcal{A}} e^{\hat{v}(a_j, \mathbf{x})/\sigma_e} \right) \right] \quad (12)$$

In practice this is done by iterating back-and-forth between the three equations until convergence. To ease computational burden, I solve for a simpler version of the model. First, I limit the number of firms to 3. This is a good approximation of the competitive environment in my data, since firm-count at the market-year level has a median of 2. Second, I do not allow for entry. This rules out firms acquiring reputation for entry deterrence. This is a reasonable assumption to make because I find no evidence of entry deterrence through reputation in my data, as well as because entry happens in less than 10% of market-year observations. Third, I do not allow for exit, again because of how infrequently it is observed in the data.

In my counterfactuals I also want to test if differentiated hospices react differently based

on their characteristics and unobserved demand shocks. To be precise, I can rewrite the demand model as:

$$\begin{aligned} u_{ijt} &= \alpha_{m(j)} + X'_{jt}\beta + \psi_{jt} + \xi_{jt} + \zeta_i + (1 - \sigma)\tilde{\varepsilon}_{ijt} \\ &= \Pi_{jt} + \psi_{jt} + \zeta_i + (1 - \sigma)\tilde{\varepsilon}_{ijt} \end{aligned}$$

where $\Pi_{jt} = \alpha_{m(j)} + X'_{jt}\beta + \xi_{jt}$ reflects how much hospice j differentiates along non-reputation dimensions. A hospice with higher Π_j can be thought to have more favorable characteristics and persistent demand shocks than others. In my counterfactuals, I test whether hospices with different Π_j respond differently to policy changes. For the sake of clarity, I impose in my counterfactuals that a hospice's Π_j remains constant over time. This matches reality well, as I find that my estimated Π_{jt} from the demand model is highly persistent.

Counterfactual results are reported as follows. For a given policy experiment, I solve the nested fixed-point problem to obtain the CCPs $\Psi(\cdot|\mathbf{x})$. The CCP gives the probability of a firm making each action choice for any given state under the chosen policy experiment. I pick a starting point for a market, then simulate forward 1000 periods. I report the average quality choice by each firm over the simulation. To prevent my choice of initial conditions from contaminating the result, the first 200 periods are dropped; additionally I check by visual inspection to ensure that the industry has settled into its long-run state.

8.2 Counterfactual results

8.2.1 Increasing persistence of reputation

The first set of counterfactuals involve the persistence of reputation. From the perspective of understanding the model, it is important to know how firms would choose quality if reputation was more persistent, or if it decayed faster. From the perspective of policymaking, this can tell us whether policy changes that lead to greater reputation persistence can improve consumer welfare. For instance, in 2017 CMS launched Hospice Compare, a website that details quality information about hospices. Such review websites can aggregate and sustain information on hospices' quality choices for much longer and with greater accuracy, and can be thought of as helping reputation persist longer. Figure 1 looks at how the average visits-per-patient varies as reputation becomes less persistent. The takeaway is that quality choice falls as reputation decays faster. The intuition is that the marginal gain from increasing quality is smaller; since reputation is decaying more quickly, an increase in quality leads to a smaller increase in future sales, so it is no longer optimal to incur the higher cost from higher




Figure 1: Average quality choice by undifferentiated hospice against reputation decay rates.

quality. This also highlights the importance of reputation in a regulated price environment; if reputation were not present, firms would choose much lower quality.

8.2.2 Increasing Medicare payments:

Medical providers have frequently complained that Medicare reimbursement rates are too low. To see how hospices react to higher reimbursement rates, my second counterfactual set of counterfactuals study how hospice quality changes as prices increase. Figure 2 reports a counterfactual where 3 identical firms make quality choices under different reimbursement rates. It can be seen that higher regulated prices lead to higher qualities being chosen by each firm. I also contrast the equilibrium quality choices at the estimated decay rate of 53% with those at a higher decay rate of 90%. This further illustrates the importance of reputation effects when predicting quality choices at a given Medicare rate.

To see how hospice differentiation along non-reputation dimensions can influence results, Figure 3 reports the same counterfactual but this time Π_j is allowed to vary between the three firms. Firms which have rivals closer to them in the product space (i.e. there is another firm with Π_j close to its own) react more strongly to an increase in price. In Figure 3a, Firm 1 is the only one with $\Pi = -2$, and does not react as much to an increase in price. In Figure 3b, Firms 1 and 3 both have $\Pi = -2$; this time, Firm 1 reacts more strongly to an increase in price.




Figure 2: Average quality choice by hospice against increasing Medicare rates, at decay rates of 0.53 and 0.9. $\Pi_1 = \Pi_2 = \Pi_3 = -1$.




Figure 3: Average quality choice by differentiated hospices against Medicare rates.

8.2.3 Subsidizing individual visits

My final set of counterfactuals investigate alternative reimbursement schemes. The current reimbursement scheme involves Medicare paying hospices for every day a patient is enrolled, i.e. a per-day scheme. Since we want to achieve high quality at the lowest possible cost, a natural route to investigate is to tie part of the reimbursement to level of quality. To that end, I solve the model for hybrid per-day per-visit schemes. I progressively reduce the per-day rate and increase the per-visit rate while ensuring that under the new terms, the equilibrium quality choice remains at 29 visits-per-patient (the median visits-per-patient observed in my data). The results are shown in Table 9. The takeaway is that potential cost savings can be achieved by shifting weight from per-day to per-visit reimbursement. Note that how far

| Per-day rate | Per-visit rate | Medicare cost |
|--------------|----------------|---------------|
| 186.7 | 0.0 | 1.0 |
| 150.0 | 50.0 | 0.93 |
| 100.0 | 110.0 | 0.82 |
| 50.0 | 170.0 | 0.71 |

Table 9: Reimbursement schemes that lead to 29 visits-per-patient by three (identical) hospices. The Medicare cost associated with each scheme is normalized with respect to the cost of the per-day scheme.

I can increase the per-visit rate is limited by the estimated marginal cost of \$200, since a per-visit rate exceeding the marginal cost will lead to hospices making unlimited visits to maximize profits.¹⁰

8.3 Discussion

One caveat that should be kept in mind when interpreting the counterfactuals is that I show how different policy levers can be used to achieve a quality target, but am silent on what the quality target should be. This is because my demand model is silent about consumer valuation of visits. The thought experiment is that CMS has figured out the quality target through studies of their own, and can achieve said target with the policy instruments I have detailed above.

9 Conclusion

In this paper, I study how hospices accumulate reputation over time through quality choices, and how different policy regulations affect hospice actions in this setting. Hospices offer palliative care to terminally ill patients, and are often chosen through suggestions by others in the patient’s healthcare team and community. The hospice industry is a nice setting for studying reputation because quality of service can be measured accurately (average visits per patient), the type of care provided is relatively low-skill, and reimbursement rates are set by Medicare on a per-day basis. I leverage yearly firm-level data to study reputation effects

¹⁰A possible issue is that per-visit schemes could encourage spurious visits by hospices to maximize profits. While my model cannot allow for firms making spurious visits, it is interesting to think about how this might play out in the real world. First, since reputation effects are salient in this industry, a hospice that makes spurious visits can develop a bad reputation and lose future consumers, so reputation effects might rein in such issues. Second, Medicare can take additional steps to discourage spurious visits. It can adopt finer contract structures (such as reimbursing hospices for up to 3 visits a week). It can also enforce stronger monitoring.

and policy regulations in California.

First, I estimate a structural model of demand to identify the importance of reputation in this setting. This involves estimating a nested-logit discrete choice model of hospice selection with persistent unobserved demand shocks and a reputation transition equation. The reputation stock accounts for the idea that a hospice can build up its reputation by consistently choosing high quality. I transform the discrete-choice equation using the inversion from [Berry \(1994\)](#), then estimate all three equations simultaneously via nonlinear 2-step GMM.

Finding reputation to have significant influence on consumer choice, I estimate a structural model of forward-looking hospices choosing quality over time to the cost function of hospices in my data. The model incorporates the estimated demand and reputation transition equation. This is estimated using [Bajari et al. \(2007\)](#). I find that the marginal cost of an additional visit is roughly \$200, for-profits enjoy a cost advantage over non-profits, and hospices in rural areas suffer from a cost disadvantage.

Armed with these parameters, I conduct several counterfactuals to see how changes in the economic environment affect hospice quality choices and shed light on optimal regulation in this setting. Higher Medicare rates lead to higher quality choices by hospices, but the effect depends on hospice characteristics and competition in the product space. Higher persistence of reputation (which may be brought about by a review site that centralizes and aggregates quality information from the past) also lead to higher quality choice by hospices. An expansion in the market size leads to a small improvement in quality choices. Finally, I show that switching to a hybrid per-day per-visit reimbursement scheme results in cost savings compared to the current per-day scheme while maintaining the same level of quality.

There are several extensions that can be explored in future work. First, my counterfactuals shed light on how different regulations affect hospice quality choices, but they are silent on what the optimal regulation should be. For that, we would need to gauge how much the society values each hospice visit to a patient, then figure out the reimbursement scheme that incentivizes hospices to choose the socially optimal quality level. Second, the dynamic oligopoly estimation currently does not allow for hospices to transition between different types over time. An alternative model of reputation could incorporate firms transitioning between cost types over time, and consumers using recent quality choices to infer a firm's cost type. This would involve incorporating a firm-specific unobservable that changes via a Markov process. Dynamic oligopoly estimation in such a setting is extremely difficult; it would involve either fully solving the model or using a variant of [Arcidiacono and Miller \(2011\)](#) to try and estimate such unobserved firm-level heterogeneity. In any setting that is difficult; in my setting with quality choice taking 6 possible values and without a terminal

action, it might not be realistic to implement. A fruitful direction of future research could be estimating a reputation accumulation model with type transitions, and doing so in a computationally tractable manner.

A Additional summary statistics

A.1 Length of stay

| Length of stay | % of patients |
|----------------|---------------|
| 0-7 days | 30.89 |
| 8-30 days | 29.38 |
| 31-90 days | 21.7 |
| 91-179 days | 9.52 |
| 180+ days | 8.51 |

Table 10: Distribution of patient length-of-stay.

| | 10% | 25% | 50% | 75% | 90% |
|-------------|-------|-------|-------|-------|-------|
| 0-7 days | 19.76 | 24.66 | 30.3 | 36.31 | 41.81 |
| 8-30 days | 21.93 | 25.05 | 29.29 | 33.01 | 36.33 |
| 31-90 days | 16.15 | 18.9 | 21.7 | 25.17 | 29.44 |
| 91-179 days | 5.45 | 7.47 | 9.41 | 11.43 | 13.92 |
| 180 days | 2.24 | 4.48 | 7.2 | 10.73 | 14.52 |

Table 11: Distribution of shares of lengths-of-stay of patients. Each observation is at the hospice-year level.

A.2 Disease category

| Diagnosis | % of patients |
|--------------|---------------|
| Cancer | 39.6 |
| Heart | 10.27 |
| Dementia | 13.57 |
| Lung | 6.39 |
| Kidney | 2.49 |
| Brain stroke | 4.47 |

| | 10% | 25% | 50% | 75% | 90% |
|---------------|-------|-------|-------|-------|-------|
| Cancer | 24.23 | 31.25 | 39.63 | 49.42 | 60.0 |
| Non cancer | 40.0 | 50.52 | 60.36 | 68.75 | 75.73 |
| Heart disease | 3.91 | 6.67 | 9.81 | 13.29 | 17.82 |
| Dementia | 3.33 | 6.5 | 11.72 | 18.03 | 25.0 |
| Lung disease | 2.61 | 4.27 | 6.18 | 8.46 | 11.12 |
| Kidney | 0.0 | 1.34 | 2.32 | 3.49 | 5.21 |
| Liver | 0.0 | 0.98 | 1.85 | 2.91 | 4.3 |
| Brain stroke | 0.0 | 1.53 | 3.48 | 5.89 | 8.96 |
| HIV | 0.0 | 0.0 | 0.0 | 0.13 | 0.46 |
| Coma | 0.0 | 0.0 | 0.0 | 0.0 | 0.35 |
| Diabetes | 0.0 | 0.0 | 0.0 | 0.0 | 0.44 |
| ALS | 0.0 | 0.0 | 0.26 | 0.61 | 1.03 |

Table 12: Distribution of shares of patients at a hospice per disease category. Each observation is at the hospice-year level.

B Miscellaneous

B.1 Relevant webpages

1. The raw datasets can be accessed here: data.chhs.ca.gov/dataset/home-health-hospice-annual-utilization-report-complete-data-set
2. Details about Medicare’s reimbursement policy can be found here: <https://www.medicare.gov/coverage/hospice-care>.
3. Some websites which detail my claim on how hospices are chosen can be found in the following:
 - <https://www.vitas.com/hospice-and-palliative-care-basics/when-is-it-time-for-hospice/how-to-choose-a-hospice-provider>
 - <https://www.cancer.org/treatment/end-of-life-care/hospice-care/how-to-find.html>
 - <https://www.health.harvard.edu/staying-healthy/choosing-hospice>
 - <https://hospicefoundation.org/End-of-Life-Support-and-Resources/Coping-with-Terminal-Illness/How-to-Choose>

- <https://rainbowhospice.org/hospice-care/choosing-hospice/>

4. Some quotes on how reputation should be considered when choosing a hospice are as follows.

- AmericanHospice.org: What do others say about this hospice? Get references both from people you know and from people in the field – e.g., local hospitals, nursing homes, clinicians. Ask anyone that you have connections to if they have had experience with the hospice and what their impressions are. Geriatric care managers can be a particularly good resource, as they often make referrals to hospices and hear from families about the care that was provided... How long has the hospice been in operation? If it has been around for a while, that’s an indication of stability.”
- HospiceFoundation.org: “Seek professional opinions. Ask clinicians, professional caregivers at nursing homes, geriatric care managers, or end-of-life doulas about their experience with a hospice. Talk to friends, family, and neighbors who have used hospice services and get their opinions about the experience with a provider.”
- Vitas.com: “Evaluate the hospice provider’s history and reputation before you decide. How long has it been in business? ... What do other patients or families say about their experiences?”
- Caringinfo.org: “Most hospice programs use family satisfaction surveys to obtain feedback about their services so they can make improvements. Ask the hospice to share a summary of their family satisfaction scores for the last several months with you. You can also ask to see their latest state or Medicare inspection report to see if there are care provision problems. Finally, you could ask to see the hospice provider’s list of complaints from the past 12 months.”

B.2 Example of a hospice reimbursement scheme

| LOCATION BY COUNTIES | ROUTINE HOME CARE DAYS 1-60 | ROUTINE HOME CARE DAYS 61+ | SERVICE INTENSITY ADD-ON (HOURLY) | CONTINUOUS CARE (HOURLY) | INPATIENT RESPITE CARE | GENERAL INPATIENT CARE |
|------------------------|--------------------------------------|-------------------------------------|--|--------------------------------|------------------------------|------------------------------|
| | Revenue Code 0650 | Revenue Code 0659 | Revenue Code 0552 | Revenue Code 0652 | Revenue Code 0655 | Revenue Code 0656 |
| NATIONAL RATES | \$ 196.50 | \$ 154.41 | \$ 41.57 | \$ 41.57 | \$ 185.27 | \$ 758.07 |
| RURAL AREAS | \$ 237.03 | \$ 186.26 | \$ 50.15 | \$ 50.15 | \$ 215.38 | \$ 903.74 |
| ALAMEDA & CONTRA COSTA | \$ 294.39 | \$ 231.33 | \$ 62.28 | \$ 62.28 | \$ 257.98 | \$ 1,109.87 |
| BUTTE | \$ 214.74 | \$ 168.74 | \$ 45.43 | \$ 45.43 | \$ 198.82 | \$ 823.63 |
| FRESNO | \$ 208.62 | \$ 163.94 | \$ 44.14 | \$ 44.14 | \$ 194.28 | \$ 801.64 |
| IMPERIAL | \$ 180.42 | \$ 141.77 | \$ 38.17 | \$ 38.17 | \$ 173.33 | \$ 700.28 |
| KERN | \$ 223.41 | \$ 175.56 | \$ 47.26 | \$ 47.26 | \$ 205.26 | \$ 854.78 |
| KINGS | \$ 206.61 | \$ 162.36 | \$ 43.71 | \$ 43.71 | \$ 192.78 | \$ 794.41 |
| LOS ANGELES | \$ 234.05 | \$ 183.92 | \$ 49.52 | \$ 49.52 | \$ 213.16 | \$ 893.02 |

References

- Arcidiacono, Peter and Robert A. Miller (2011) “Conditional Choice Probability Estimation of Dynamic Discrete Choice Models With Unobserved Heterogeneity,” *Econometrica*, 79, 1823–1867, DOI: [10.3982/ECTA7743](https://doi.org/10.3982/ECTA7743).
- Bai, Jie (2022) “Melons as Lemons: Asymmetric Information, Consumer Learning and Seller Reputation | Harvard Kennedy School.”
- Bajari, Patrick, C. Lanier Benkard, and Jonathan Levin (2007) “Estimating Dynamic Models of Imperfect Competition,” *Econometrica*, 75, 1331–1370, DOI: [10.1111/J.1468-0262.2007.00796.X](https://doi.org/10.1111/J.1468-0262.2007.00796.X).
- Benkard, C. Lanier (2004) “A Dynamic Analysis of the Market for Wide-Bodied Commercial Aircraft,” *The Review of Economic Studies*, 71, 581–611, DOI: [10.1111/J.1467-937X.2004.00297.X](https://doi.org/10.1111/J.1467-937X.2004.00297.X).
- Berry, Steven, James Levinsohn, and Ariel Pakes (1995) “Automobile Prices in Market Equilibrium,” *Econometrica*, 63, 841, DOI: [10.2307/2171802](https://doi.org/10.2307/2171802).
- Berry, Steven T. (1994) “Estimating Discrete-Choice Models of Product Differentiation,” *The RAND Journal of Economics*, 25, 242, DOI: [10.2307/2555829](https://doi.org/10.2307/2555829).

- Borkovsky, Ron N., Avi Goldfarb, Avery M. Haviv, and Sridhar Moorthy (2017) “Measuring and Understanding Brand Value in a Dynamic Model of Brand Management,” <https://doi.org/10.1287/mksc.2016.1020>, 36, 471–499, DOI: [10.1287/MKSC.2016.1020](https://doi.org/10.1287/MKSC.2016.1020).
- Bronnenberg, Bart J., Jean-Pierre Dubé, and Chad Syverson (2022) “Marketing Investment and Intangible Brand Capital,” *Journal of Economic Perspectives*, 36, 53–74, DOI: [10.1257/JEP.36.3.53](https://doi.org/10.1257/JEP.36.3.53).
- Cabral, Luís and Ali Hortaçsu (2010) “THE DYNAMICS OF SELLER REPUTATION: EVIDENCE FROM EBAY*,” *The Journal of Industrial Economics*, 58, 54–78, DOI: [10.1111/J.1467-6451.2010.00405.X](https://doi.org/10.1111/J.1467-6451.2010.00405.X).
- Chung, Andrea P and Alan Sorensen (2018) “For-Profit Entry and Market Expansion in the Hospice Industry.”
- Collard-Wexler, Allan (2013) “Demand Fluctuations in the Ready-Mix Concrete Industry,” *Econometrica*, 81, 1003–1037, DOI: [10.3982/ECTA6877](https://doi.org/10.3982/ECTA6877).
- Dubé, Jean Pierre, Günter J. Hitsch, and Puneet Manchanda (2005) “An Empirical Model of Advertising Dynamics,” *Quantitative Marketing and Economics 2005 3:2*, 3, 107–144, DOI: [10.1007/S11129-005-0334-2](https://doi.org/10.1007/S11129-005-0334-2).
- Ericson, Richard and Ariel Pakes (1995) “Markov-Perfect Industry Dynamics: A Framework for Empirical Work,” *The Review of Economic Studies*, 62, 53–82, DOI: [10.2307/2297841](https://doi.org/10.2307/2297841).
- Fudenberg, Drew and Jean Tirole (1991) *Game Theory*: MIT Press.
- Gaynor, Martin, Rodrigo Moreno-Serra, and Carol Propper (2013) “Death by Market Power: Reform, Competition, and Patient Outcomes in the National Health Service,” *American Economic Journal: Economic Policy*, 5, 134–66, DOI: [10.1257/POL.5.4.134](https://doi.org/10.1257/POL.5.4.134).
- Grennan, Matthew (2013) “Price Discrimination and Bargaining: Empirical Evidence from Medical Devices,” *American Economic Review*, 103, 145–77, DOI: [10.1257/AER.103.1.145](https://doi.org/10.1257/AER.103.1.145).
- Hackmann, Martin B. (2019) “Incentivizing Better Quality of Care: The Role of Medicaid and Competition in the Nursing Home Industry,” *American Economic Review*, 109, 1684–1716, DOI: [10.1257/AER.20151057](https://doi.org/10.1257/AER.20151057).
- Jin, Ginger Zhe and Phillip Leslie (2009) “Reputational Incentives for Restaurant Hygiene,” *American Economic Journal: Microeconomics*, 1, 237–67, DOI: [10.1257/MIC.1.1.237](https://doi.org/10.1257/MIC.1.1.237).

- Lee, Robin S. (2013) “Vertical Integration and Exclusivity in Platform and Two-Sided Markets,” *American Economic Review*, 103, 2960–3000, DOI: [10.1257/AER.103.7.2960](https://doi.org/10.1257/AER.103.7.2960).
- Lin, Haizhen (2015) “QUALITY CHOICE AND MARKET STRUCTURE: A DYNAMIC ANALYSIS OF NURSING HOME OLIGOPOLIES,” *International Economic Review*, 56, 1261–1290, DOI: [10.1111/IERE.12137](https://doi.org/10.1111/IERE.12137).
- Olley, G. Steven and Ariel Pakes (1996) “The Dynamics of Productivity in the Telecommunications Equipment Industry,” *Econometrica*, 64, 1263, DOI: [10.2307/2171831](https://doi.org/10.2307/2171831).
- Pakes, Ariel, Michael Ostrovsky, and Steven Berry (2007) “Simple estimators for the parameters of discrete dynamic games (with entry/exit examples),” *The RAND Journal of Economics*, 38, 373–399, DOI: [10.1111/J.1756-2171.2007.TB00073.X](https://doi.org/10.1111/J.1756-2171.2007.TB00073.X).
- Rust, John (1987) “Optimal Replacement of GMC Bus Engines: An Empirical Model of Harold Zurcher,” *Econometrica*, 55, 999, DOI: [10.2307/1911259](https://doi.org/10.2307/1911259).
- Saeedi, Maryam (2019) “Reputation and adverse selection: theory and evidence from eBay,” *The RAND Journal of Economics*, 50, 822–853, DOI: [10.1111/1756-2171.12297](https://doi.org/10.1111/1756-2171.12297).
- Tadelis, Steven (2016) “Reputation and Feedback Systems in Online Platform Markets,” <http://dx.doi.org/10.1146/annurev-economics-080315-015325>, 8, 321–340, DOI: [10.1146/ANNUREV-ECONOMICS-080315-015325](https://doi.org/10.1146/ANNUREV-ECONOMICS-080315-015325).
- Wang, Yanfei (2022) “COMPETITION AND MULTILEVEL TECHNOLOGY ADOPTION: A DYNAMIC ANALYSIS OF ELECTRONIC MEDICAL RECORDS ADOPTION IN U.S. HOSPITALS,” *International Economic Review*, 63, 1357–1395, DOI: [10.1111/IERE.12586](https://doi.org/10.1111/IERE.12586).
- Weintraub, Gabriel Y., C. Lanier Benkard, and Benjamin Van Roy (2008) “Markov Perfect Industry Dynamics With Many Firms,” *Econometrica*, 76, 1375–1411, DOI: [10.3982/ECTA6158](https://doi.org/10.3982/ECTA6158).